NPPA and hydrops fetalis: ANP/MR-proANP and other biomarkers may help to interpret the clinical meaning of changes in BNP/NT-proBNP levels during neprilysin inhibition and to improve biomarker-guided disease management and, ultimately, the outcomes of patients with HF.